Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer

Date Posted: 
2021-09-08

Dr. Zoubeidi led an international team that has published their discovery providing mechanistic insights into prostate cancer resistant to powerful hormone therapy, and proposes a potential treatment regime for reversing currently treatment-resistant phenotypes. This work was published online on September 6, 2021 in the high-impact journal Nature Cell Biology , along with a News and Views article focusing on this publication.

The team investigated a phenomenon in prostate cancer in which tumours can escape epithelial lineage confinement and transition to a high-plasticity state as an adaptive response to potent androgen receptor (AR) antagonism. Their study demonstrates that targeting both AR and EZH2 in patients with AR-positive, neuroendocrine-like tumours has the potential to reprogram aggressive tumours to a targetable state. This work highlights the clinical potential of reversing resistant phenotype.


Acknowledgements
This research was supported by funding from the Terry Fox Research Institute New Frontiers Program Project Grant (to A.Z.), the Prostate Cancer Foundation (to A.Z. and H.B.), and the Canadian Institutes of Health Research (399802 to A.D.)


Davies A, Nouruzi S, Ganguli D, Namekawa T, Thaper D, Linder S, Karaoğlanoğlu F, Omur ME, Kim S, Kobelev M, Kumar S, Sivak O, Bostock C, Bishop J, Hoogstraat M, Talal A, Stelloo S, van der Poel H, Bergman AM, Ahmed M, Fazli L, Huang H, Tilley W, Goodrich D, Feng FY, Gleave M, He HH, Hach F, Zwart W, Beltran H, Selth L, Zoubeidi A. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021 Sep 6. doi: 10.1038/s41556-021-00743-5. Epub ahead of print. PMID: 34489572

News and Views: Xin L. EZH2 accompanies prostate cancer progression. Nat Cell Biol. 2021 Sep 6. doi: 10.1038/s41556-021-00744-4. Epub ahead of print. PMID: 34489575  

A World Class Centre

The Vancouver Prostate Centre (VPC) has a track record of success that has earned it a reputation as one of the world’s most respected cancer facilities. It is a National Centre of Excellence and a designated Centre of Excellence for Commercialization and Research.

Events

Employment

Work at the Vancouver Prostate Centre

Monday, November 1, 2021

Dr. Syam Somasekharan appointed Senior Research Scientist

Dr. Syam Somasekharan
Wednesday, September 8, 2021

Recent publication proposes a potential new therapeutic approach to treatment-resistant prostate cancer